| Name | Title | Contact Details |
|---|
LaBelle Strategic Resources is a Collegeville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Landmark Health Solutions Company is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We empower greater health. Today, we have access to highly personalized and useful information in almost every area of our lives; our money, transportation, food, exercise, entertainment, and home security yet we don’t have this same access to the data and insights contained in our personal health records. The current healthcare system is highly complex and constrains the flow of useful information; patient health data and medical records are stored in hundreds of different systems, across thousands of independent organizations in millions of different formats. We simplify this complexity to securely connect healthcare decision-makers to the clinical data and hidden insights contained in patent medical records so that they can deliver greater outcomes at lower costs.
Excelera is a national network of academic medical centers and integrated delivery networks with specialty pharmacy capabilities. Excelera supports its members by using sophisticated data management, reporting and analytical capabilities; secures access to limited distribution specialty pharmaceuticals; and provides clinical care protocols and best practices. Excelera is grounded in the simple premise that health systems, along with their specialist physicians, are best equipped to produce optimal health and financial outcomes for complex patients because they are the central hub for coordinating and integrating care needs, managing the electronic medical record, and providing a high-touch local service.
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).